Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Meningococcal (vaccine)
Meningococcal · 3 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Meningococcal Vaccine | BIOLOGICAL | - |
| Meningococcal (vaccine) | BIOLOGICAL | - |
Inclusion Criteria: * Healthy male or female between, and including, 15 and 19 years of age at the time of vaccination. * Subject with previously completed routine childhood vaccinations to the best of his/her knowledge or his/her parents'/guardians' knowledge. * Female subjects should be of non-ch...
The Meningococcal vaccine is an investigational vaccine developed by GSK plc for the prevention of meningococcal infections. It targets meningococcal serogroups A, C, W-135, and Y, and is being studied in healthy adolescent and young adult volunteers. It is a vaccine modality in the infectious disease therapeutic area.
The Meningococcal vaccine is being studied for the prevention of infections caused by meningococcal serogroups A, C, W-135, and Y. Clinical trials have enrolled healthy subjects aged 15 to 25 years. The vaccine is investigational and has not been established as an approved product based on the available development information.
GSK plc, which trades under the ticker GSK, is the developer of the Meningococcal vaccine. The company has sponsored Phase 2 clinical trials evaluating different formulations of the vaccine in healthy volunteers.
The Meningococcal vaccine is in Phase 2 clinical development. All three of its recorded trials are Phase 2 studies, and all three have been completed. No active trials are currently listed, and the vaccine remains investigational rather than approved.
Three completed Phase 2 trials have evaluated the Meningococcal vaccine: NCT00196963 in Belgium with 125 subjects, NCT00196950 in Belgium with 50 subjects, and NCT00126945 in Denmark with 125 subjects. Together these studies enrolled approximately 300 healthy volunteers aged 15 to 25 years.
Yes. Meningococcal, Meningococcal (vaccine), and Meningococcal Vaccine are alternative names for the same GSK plc vaccine candidate. All refer to the investigational vaccine targeting meningococcal serogroups A, C, W-135, and Y that GSK is developing in Phase 2 trials.